Xtl Biopharmaceuticals (XTLB) Gross Margin (2011 - 2024)

Xtl Biopharmaceuticals (XTLB) posted quarterly Gross Margin of 14.88% for Q4 2024, down 125.72% on a QoQ basis from 57.84% in Q3 2014.

Xtl Biopharmaceuticals (XTLB) Gross Margin (2011 - 2024) Analysis & Trends

Xtl Biopharmaceuticals (XTLB) has reported Gross Margin for 5 consecutive years, with 14.88% the latest figure, recorded in Q4 2024.

Quarterly Gross Margin changed N/A year-over-year to 14.88% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 36.8% (changed N/A YoY) and the FY2024 annual result came in at 0.67%, changed N/A from the prior year.
Gross Margin retreated to 14.88% in Q4 2024 per XTLB's latest filing, from 57.84% in the prior quarter.
Over the last five years, Gross Margin for XTLB reached as high as 14.88% in Q4 2024 and fell as low as 14.88% in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn	88.95%
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn	86.85%
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn	91.79%
7	Belite Bio	62.72 Bn	62.72 Bn	-	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn	90.68%
9	Revolution Medicines	37.35 Bn	37.35 Bn	-	-
10	Xtl Biopharmaceuticals	2.58 Bn	2.58 Bn	-	-

Download Data